An observational study in Bronchopulmonary Dysplasia (BPD), Mortality Prediction and Chloride Disorder, sponsored by Kanuni Sultan Suleyman Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 1 Hour to 6 Weeks. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Kanuni Sultan Suleyman Training and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Bronchopulmonary Dysplasia with a site in Turkey — 2 open to participants now, 2 under way, none of them phase 3. Bronchopulmonary Dysplasia · Turkey.
Among the 13 studies in Bronchopulmonary Dysplasia with a site in Turkey, this one is the only one that started in 2025, is one of 5 observational ones, and was the 11th registered.
362 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.
Browse Bronchopulmonary Dysplasia studies →2 of the 13 studies in Bronchopulmonary Dysplasia with a site in Turkey are open now. Recruiting first, the newest first:
Konya City Hospital · Sites in Turkey
Ages 0 days–28 days
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 58 Bronchopulmonary Dysplasia studies recruiting now, 7 (12%) set no upper age limit and 50 (86%) stop at 75 or younger; 56 take children under 18; 11 take healthy volunteers.
This study: 1 Hour to 6 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 150 across 99 observational studies indexed under Bronchopulmonary Dysplasia.
Median enrollment 123 across the 8 interventional studies, 80 across the 5 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Kanuni Sultan Suleyman Training and Research Hospital is the lead sponsor of 225 studies on the registry; 35 are open to participants now.
Kanuni Sultan Suleyman Training and Research Hospital has 1 study filed under Bronchopulmonary Dysplasia — fewer than ten, so there is no comparison to draw.
2 of the studies in Bronchopulmonary Dysplasia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07525167Konya City HospitalEarly Prediction of Bronchopulmonary Dysplasia in Preterm Infants Using Clinical Data | 2026-12-01 |
| NCT06940856Kanuni Sultan Suleyman Training and Research HospitalChloride Imbalance in Preterm Infants | 2027-04-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Bronchopulmonary Dysplasia with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In adults and children low or high blood chloride levels are linked to the risk of death. The aim of this observational study is to determine whether there is a relationship between low or high blood chloride levels and the risk of death or long-term lung problems. We will also learn the risk factors and associated conditions of high or low blood chloride levels. We will include infants born before 32 weeks of pregnancy or have a birth weight of less than 1500 grams in the study. The main question it aims to answer is:
Is there a relationship between low or high blood chloride levels in the first 4-6 weeks of life and risk of death or long-term lung problems in premature babies? We will examine the medical reports of babies who were followed up in neonatal intensive care unit over the past 5 years.
Chloride balance usually parallels that of sodium, and it is strictly correlated to the extracellular volume balance. In addition plasma chloride and bicarbonate concentrations are inversely regulated through the chloride-bicarbonate exchange pump in renal collecting ducts, independent of sodium. Consequently, plasma chloride levels are closely correlated with pH (hypochloremia/metabolic alkalosis, hyperchloremia/metabolic acidosis).
In adults, dyschloremia is associated with mortality, acute kidney injury, and prolonged hospital stay. Hyperchloremia is often associated with severe sepsis. It has been shown that resuscitation with high-chloride fluids (eg: saline solution) instead of balanced fluids (e.g., Ringer's lactate) increases the need for inotropes in critically ill adults. Similarly, hyperchloremia in septic pediatric patients is linked to acute renal injury requiring dialysis, increased inotropic support, and mortality. In 1979, infants fed with chloride-deficient formula were reported to develop impaired head growth and neurologic sequelae.
Although serum chloride is routinely measured in neonatal intensive care units, its clinical significance is often overlooked. For this reason unlike sodium, literature on chloride metabolism in preterm infants is exceedingly limited.
Advancements in perinatal care over the past 50 years have significantly improved survival rates in preterm infants. However, a large proportion of very preterm infants who survive the neonatal period develop bronchopulmonary dysplasia (BPD). BPD, a chronic lung disease, manifests clinically through persistent respiratory support and/or oxygen dependency. Despite efforts to optimize neonatal care -such as controlled oxygen usage, non-invasive ventilation, volume-guarantee techniques, high-frequency ventilation, and caffeine therapy- BPD remains the most common complication among preterm infants and is associated with increased morbidity and mortality.
It has been suggested that extracellular volume expansion (edema) plays a role in the pathophysiology of BPD. Perlman et al.'s 1986 study demonstrated that infants who died from BPD exhibited hypochloremia, metabolic alkalosis, and complications like inadequate head growth, more frequently than those who survived. These findings highlight the critical importance of chloride imbalance in neonates, similar to findings in adult and pediatric populations.
This study aims to investigate the relationship between chloride balance and two major outcomes-mortality and the development of BPD-in preterm infants. Infants \<32 weeks postmentruel age (PMA) or weighing less than 1500 grams will be enrolled in the study. We also plan to explore the relationship of dyschloremia with other outcomes of prematurity (eg: patent ductus arteriosus, ventilator dependency, retinopathy of prematurity (ROP), necrotizing enterocolitis, intraventricular hemorrhage, periventricular leukomalacia, hospital stay. Lastly we plan to explore the risk factors and clinical/laboratory conditions that are associated with chloride level abnormalities.
If this study yields findings that underscore the clinical significance of chloride levels in preterm infants, similar to adults and children, then close monitoring of chloride balance and appropriate interventions could potentially reduce mortality and BPD incidence in preterm infants. Conversely, if results indicate that chloride balance lacks clinical significance in preterm infants, this will also contribute valuable information to the current literature.
Study population includes infants admitted to the Neonatal Intensive Care Unit at Kanuni Sultan Suleyman Training and Research Hospital over the past 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Infants with serum chloride levels within reference range before 36 weeks PMA
Other: Incomplete response · Other: Complete response · Other: Bad response
Infants with serum chloride levels \<96 mEq/l and \>110 mEq/l before 36 weeks PMA
Other: Incomplete response · Other: Complete response · Other: Bad response
Infants died before 36 weeks PMA, infants diagnosed to have BPD at 36 weeks PMA and infants developed major complications before 36 weeks PMA: 1. \>Stage 2 necrotizing enterocolitis according to Bell classification 2. Hemodynamically significant patent ductus arteriosus 3. \>Grade 2 intraventricular hemorrhage, 4. Retinopathy of prematurity, ICROP classification stage \>2 5. \>Stage 2 cystic periventricular leukomalacia 6. Ventricular dilatation/hydrocephalus requiring intervention
Infants discharged before 36 weeks PMA and infants who reached 36 weeks PMA without BPD and major complications: 1. \>Stage 2 necrotizing enterocolitis according to Bell classification 2. Hemodynamically significant patent ductus arteriosus 3. \>Grade 2 intraventricular hemorrhage, 4. Retinopathy of prematurity, ICROP classification stage \>2 5. \>Stage 2 cystic periventricular leukomalacia 6. Ventricular dilatation/hydrocephalus requiring intervention
Infants died before 36 weeks PMA and infants diagnosed to have BPD at 36 weeks PMA
BPD
BPD at 36 weeks PMA
Time frame: From enrollment to the end of 36 weeks PMA
Mortality
Mortality within 36 weeks PMA
Time frame: From enrollment to the end of 36 weeks PMA
NEC
\>Stage 2 necrotizing enterocolitis according to Bell classification within 36 weeks PMA
Time frame: From enrollment to the end of 36 weeks PMA
PDA
Hemodynamically significant patent ductus arteriosus within 36 weeks PMA
Time frame: From enrollment to the end of 36 weeks PMA
IVH
\>Grade 2 intraventricular hemorrhage within 36 weeks PMA
Time frame: From enrollment to the end of 36 weeks PMA
ROP
Retinopathy of prematurity, ICROP classification stage \>2 at 36 weeks PMA
Time frame: From enrollment to the end of 36 weeks PMA
PVL
\>Stage 2 cystic periventricular leukomalacia at 36 weeks PMA
Time frame: From enrollment to the end of 36 weeks PMA
Hydrocephalus
Ventricular dilatation/hydrocephalus requiring intervention at 36 weeks PMA
Time frame: From enrollment to the end of 36 weeks PMA
Plan to share: Undecided — We are not sure that local ethics committee that approved our study will allow IPD sharing
Started May 2025 (actual). Primary completion is estimated for Apr 2027, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kanuni Sultan Suleyman Training and Research Hospital →